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Abstract
IMPORTANCE Anorexia nervosa is recognized as an important cause of morbidity in young people.
However, the risk of cancer in people with anorexia nervosa remains uncertain.
OBJECTIVE To evaluate the association of anorexia nervosa with the risk of developing or dying
of cancer.
DATA SOURCES MEDLINE, Scopus, Embase, andWeb of Science from database inception to
January 9, 2019.
STUDY SELECTION Published observational studies in humans examining the risk of cancer in
people with anorexia nervosa compared with the general population or those without anorexia
nervosa. Studies needed to report incidence or mortality rate ratios (RRs).
DATA EXTRACTIONAND SYNTHESIS Screening, data extraction, andmethodological quality
assessment were performed by at least 2 researchers independently. A random-effects model was
used to synthesize individual studies. Heterogeneity (I2) was assessed and 95% prediction intervals
(PIs) were calculated.
MAINOUTCOMES ANDMEASURES All cancer incidence and cancer mortality associated with
anorexia nervosa. Secondary outcomes were site-specific cancer incidence andmortality.
RESULTS Seven cohort studies published in 10 articles (42 602 participants with anorexia nervosa)
were included. Anorexia nervosawas not associatedwith risk of developing any cancer (4 studies in
women; RR, 0.97; 95% CI, 0.89-1.06; P = .53; I2, 0%; 95% PI, 0.80-1.18; moderate confidence).
Anorexia nervosa was associated with decreased breast cancer incidence (5 studies in women; RR,
0.60; 95% CI, 0.50-0.80; P < .001; I2, 0%; 95% PI, 0.44-0.83; high confidence). Conversely,
anorexia nervosa was associated with increased risk of developing lung cancer (3 studies in women;
RR, 1.50; 95% CI, 1.06-2.12; P = .001; I2, 0%; 95% PI, 0.19-16.46; low confidence) and esophageal
cancer (2 studies in women; RR, 6.10; 95% CI, 2.30-16.18; P < .001; I2, 0%; low confidence).
CONCLUSIONS ANDRELEVANCE Among people with anorexia nervosa, risk of developing cancer
did not differ compared with the general population, but a significantly reduced risk of breast cancer
was observed. Understanding themechanisms underlying these associations could have important
preventive potential.
JAMA Network Open. 2019;2(6):e195313. doi:10.1001/jamanetworkopen.2019.5313
Key Points
Question Are people with anorexia
nervosa at a higher risk of developing or
dying of cancer compared with those
without anorexia and the general
population?
Findings In this systematic review and
meta-analysis of 7 cohort studies
includingmore than 42000
participants with anorexia nervosa,
there was no association of anorexia
nervosa with overall cancer incidence or
mortality. Anorexia nervosa was
inversely associated with breast cancer
incidence but positively associated with
risk of developing lung and
esophageal cancer.
Meaning There was no association of
anorexia nervosa with risk of cancer
overall and few associations of anorexia
nervosawith risk of site-specific cancer.
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Introduction
Almost 3.4 million young people throughout the world have anorexia nervosa.1 Anorexia nervosa is
characterized by a severe restriction of caloric intake, extremely low body weight, fear of gaining
weight or of becoming fat, and disturbance of body image. Anorexia nervosa is more commonly
reported by young women and girls, but the disorder is increasingly being reported by boys, men,
and women older than 40 years. Genetic factors and hormonal changes may influence risk,
psychosocial and interpersonal factors can trigger onset, and changes in molecular pathways and
cellular networks in the brain are associated with the illness and its comorbidities.2-4
Cancer is the second leading cause of death worldwide,5,6 with more than 9.6million deaths in
2017.6Multiple studies andmeta-analyses suggest that excess bodyweight is a risk factor of several
cancers.7-9 For example, a recent umbrella review8 found evidence of an association of body mass
index (BMI) with cancers of digestive organs, hormone-related cancers, uterine cancer, kidney
cancer, andmultiple myeloma and also of adiposity with the risk of colorectal cancer, gallbladder
cancer, gastric cancer, ovarian cancer, andmultiple myeloma. The underlying mechanisms of the
association of excess body weight with cancer are complex and are not yet fully understood.
Research on how reducing body weight might lower the risk of developing cancer is limited, to
our knowledge. Energy restriction (or calorie restriction) has been found to be protective against the
development of cancer in experimental animal studies.10 In addition, certain calorie-limited diets or
fasting could influence the risk of developing cancer. Anorexia nervosa, an excessive form of calorie
restriction associated with pathological weight loss, has been proposed as a biomarker of energy
restriction in humans.11-13 Several studies have evaluated whether there is a reduction in cancer
development among people with anorexia nervosa.12-14 However, to our knowledge, there are no
systematic reviews andmeta-analyses investigating the strength of the evidence of the potential
associations of anorexia nervosa with cancer. In this study, we aimed to evaluate the association of
anorexia nervosa with the risk of developing or dying of cancer.
Methods
We followed the current methods recommendations for systematic reviews15,16 and developed a
protocol (PROSPERO registration number: CRD42017067462)17 to comply with the Preferred
Reporting Items for Systematic Reviews andMeta-analyses (PRISMA) reporting guideline statement
for reporting this study. We also reported this study in accordance with theMeta-analysis of
Observational Studies in Epidemiology (MOOSE) reporting guideline. Ourmethods are briefly described
here and explained in more detail in the published protocol17 and in eTables 1-7 in the Supplement.
Search Strategy and Selection Criteria
One of us (A.A.-A.) searchedMEDLINE, Scopus, Embase, and theWeb of Science to identify all
relevant observational studies in humans that examined the association of anorexia nervosa with the
risk of cancer published from database inception to January 9, 2019, without language restrictions.
The main search strategy for MEDLINE is presented in eTable 3 in the Supplement. This search
strategy was adapted to fit with other databases. To supplement these searches, references of all
relevant primary studies and review articles were also screened to identify additional data sources.
To be included, primary studies had to be observational (ie, cohort or case-control) studies of
people with anorexia nervosa (according to standard operationalized diagnostic criteria, ie,
International Classification of Diseases, Ninth Revision [ICD-9] codes 307.1 or 307.54 or ICD-10 codes
F50.0-F50.1) and report the incidence or mortality rate ratios (RRs) for the risk of cancer in patients
with anorexia nervosa compared with the general population or those without anorexia nervosa or
have enough data (ie, number of cases and sample size, observed and expected cases) to compute
these estimates.We excluded studies in which anorexia nervosawas not the exposure of interest and
in which cancer was not reported as the outcome. Studies not presenting study-specific data or
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sufficient data for an outcomemeasure to be calculated were also excluded. We excluded case
reports, case series, in vitro studies, and animal studies.
Two of us (F.C.-L. and J.F.-M.) independently screened the titles and abstracts of articles
retrieved from the literature search, and the full-texts of potentially eligible articles were obtained
and further assessed for final inclusion. Disagreements were resolved through discussions until a
consensus was reached.
Outcomes
The primary outcomes were all cancer incidences and cancer mortalities (all malignant neoplasms;
ICD-9 codes 140-209; ICD-10 codes C00-C97). Given the varied biology of cancers, the risk of
incident site-specific cancers and the risk of fatal site-specific cancers were evaluated as secondary
outcomes (eTable 1 in the Supplement).
Data Extraction andQuality Assessment
Two of us (F.C.-L. and J.F.-M.) independently extracted article data, including first author, publication
year, period of recruitment, country, study design, setting, coverage, mean or median age (or age
range), proportion of female participants, race/ethnicity, parity status, profile of tobacco smoking,
ascertainment of cancer diagnosis and diagnostic criteria, consideration of confounding factors, the
number of participants with cancer, and maximally adjusted RR estimates with 95% CIs from the
included studies. For duplicate study publications, we considered only the report with themost
informative and complete data. When relevant outcome data were not available, we directly
contacted the corresponding author of the study to request the information. Two pairs of us (J.F.-M.,
M.J.P., M.R., and/or D.M.S.-G.) independently undertookmethodological quality assessment of
included studies using the Newcastle-Ottawa scale18 and allocated stars for adherence to the
prespecified criteria. This scale ranges from 0 stars (lowest quality) to 9 stars (highest quality) and
judges each study regarding selection of study groups, comparability, and ascertainment of the
outcome. We considered studies with 0 to 3 stars to represent high risk of bias; 4 to 6 stars,
moderate risk of bias; and 7 to 9 stars, low risk of bias. Discrepant scores were resolved by discussion
and consensus among us.
Statistical Analysis
Tomeasure the association of anorexia nervosa with cancer, we performedmeta-analysis using the
inverse–variance weighted random-effects model19 to pool weighted RRs of cancer risk estimates.
Random-effects meta-analysis produces a more generalizable result by considering both within-
study and between-study variation by incorporating the heterogeneity of effects into overall
analyses. We assessed heterogeneity between studies using the P value of CochranQ test20 and the
I2 statistic (with 95% CIs).21 The I2 statistic ranges from 0% to 100%, with values of 0% to 25%
indicating low heterogeneity and 75% to 100% indicating high heterogeneity.15 In comparisons that
included 3 or more studies, we also calculated the 95% prediction intervals (PIs), which further
account for heterogeneity between studies and indicate the uncertainty for the effect that would be
expected in a new study examining that same association.22 To assess the robustness of pooled
results and explore possible reasons for heterogeneity, prespecified subgroup analyses were
performed according to sex (female or male), and cancer types according to relationship with
smoking (smoking-related cancer sites or other cancer sites) or sex hormones (cancers occurring in
hormone-sensitive tissues, such as breast, ovary, uterus, prostate, and colorectal, where sex
hormones exert an important influence in cancer etiopathogenesis and progression, or other cancer
sites).17 For the secondary outcome of breast cancer incidence, we conducted a specific analysis
among women and girls based on parity status (parous or nulliparous women) and age at receiving
first diagnosis of anorexia nervosa (prior to age 20 years or at 20 years or older).13 We performed a
post hoc sensitivity analysis excluding studies that had possible geographical and temporal
overlapping study samples (eg, 2 previously published studies in Denmark12 and Sweden23-25),
JAMANetworkOpen | Oncology Association of Anorexia NervosaWith Risk of Cancer
JAMA Network Open. 2019;2(6):e195313. doi:10.1001/jamanetworkopen.2019.5313 (Reprinted) June 7, 2019 3/14
Downloaded From: https://jamanetwork.com/ by a University of Exeter User  on 06/10/2019
considering only data from the studywith the greatest person-years. P values were determined using
theWoolf method. P values were 2-tailed, and statistical significance was set at less than .001. We
conducted data analysis using themetan package in Stata statistical software version 15 (StataCorp).
With the publication of this article, the full data set will be freely available online in the Open
Science Framework (https://osf.io/Y6WQN/). We applied a set of criteria to classify the credibility of
the evidence frommeta-analysis based on the Global Burden of Disease andWorld Cancer Research
Fund criteria26,27 and GRADE system28 (eTable 7 in the Supplement).
Results
Relevant Literature Identified
We screened 358 titles and abstracts, followed by 59 full-text articles (Figure 1). Seven cohort studies
published in 10 articles,12,13,23-25,29-33 including 42 602 participants with anorexia nervosa, met our
inclusion criteria.
Description of Studies and Participants
Table 1 summarizes the characteristics of the included studies. All studies were published in English
from 2001 through 2018. Five studies were from Europe (Denmark,12,29,32 Finland,29,32
Sweden,13,23-25,29,32 and the United Kingdom31) and 2 studies30,33 were fromNorth America (the
United States). Six studies were retrospective cohorts12,13,23-25,29-32 and 1 was a prospective cohort.33
Median (range) follow-upwas 13.3 (5.4-27.1) years. The number of participants with anorexia nervosa
varied from 275 to 24 332, and the number of cancer cases ranged from 2 to 389. The proportion of
female participants varied from 60.5% to 100%.
There were 79 individual study estimates for all types of cancer and 22 site-specific cancer
outcomes (eTable 5 in the Supplement). All 7 studies provided adjusted risk estimates (eg, adjusted
for age, sex, and calendar year). Breast cancer was the most studied site-specific outcome,
accounting for 108 cases (19.8%) in 5 studies. Bladder, bone, prostate, and testicular cancer only
accounted 1 case each, representing 0.7% of all cancer cases (Figure 2). Regarding the
methodological quality (eTable 6 in the Supplement), 6 articles (86%) had low risk of bias and 1 had
moderate risk of bias (Newcastle-Ottawa Scale values, 5-8).
Figure 1. FlowDiagram of Study Selection
494 Records identified through MEDLINE, Scopus,
Embase, and Web of Science databases
548 Records found
358 Records screened
59 Full-text articles assessed for eligibility
10 Articles included in qualitative synthesis
and meta-analysis
190 Duplicates excluded
299 Records excluded as not relevant
54 Records identified through other sources
49 Excluded
36 Did not have cancer as an outcome
10 Had poor study design
3 Had nonabstractable data
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Meta-analyses
We found no difference in all cancer incidence between patients with anorexia nervosa and the
general population (4 studies in women; RR, 0.97; 95% CI, 0.89-1.06; P = .53; I2, 0%; 95% PI, 0.80-
1.18; moderate confidence) (Table 2 and Figure 3). Only 2 studies included data on cancer risk for
male participants (RR, 1.09; 95% CI, 0.73-1.65; P = .67; I2, 0%; low confidence), and 2 included data
on cancer risk among both sexes combined (RR, 0.97; 95% CI, 0.88-1.07; P = .54; I2, 0%; low
confidence). Meta-analysis for all cancer mortality was not possible, with only 1 study in women (RR,
2.00; 95% CI, 1.30-2.90; P = .001; low confidence) and 1 study in both sexes combined (RR, 0.39;
95% CI, 0.08-1.13; P = .16; low confidence).
In terms of the 22 site-specific cancers, a minority of associations of anorexia nervosa with risk
of developing cancer or death of cancer have supporting evidence (Table 2; eTable 8 in the
Supplement). Anorexia nervosa was associated with decreased breast cancer incidence compared
with the general female population (5 studies in women; RR, 0.60; 95% CI, 0.50-0.80; P < .001; I2,
0%; 95% PI, 0.44-0.83; high confidence). Conversely, we found anorexia nervosa was potentially
associated with an increased risk of developing lung cancer (3 studies in women; RR, 1.50; 95% CI,
1.06-2.12; P = .001; I2, 0%; 95% PI, 0.19-16.46; low confidence) and esophageal cancer (2 studies in
women; RR, 6.10; 95% CI, 2.30-16.18; P < .001; I2, 0%; low confidence).
No differences were found for any of the other specific sites of cancer investigated through
meta-analyses, including cancer of the brain and central nervous system, cervical cancer, lip and oral
Figure 2. Treemap Summarizing the Amount of Data According to Site-Specific Cancers
Number of cases
<5 >100
(n= 1)
6
(n= 1)
4
(n= 2)(n = 7)
1
(n= 1)
5
(n= 1)(n= 4)
3
(n= 2)
2
Pancreas
Kidney
Uterus
(n = 8)
(n = 10)
(n = 8)
Liver
Stomach
(n = 18)
Thyroid
(n = 13)
Esophagus
(n = 46)
Lung
(n = 50)
Brain and CNS
(n = 55)
Other skin cancer
(n = 43)(n = 57)
Lymphoid,
hematopoieticMalignant skin melanoma
(n = 108)
Breast
(n = 23)
Cervix
(n = 27)
Colorectal
(n = 9)
Ovary
1 indicates gallbladder; 2, lip and oral cavity; 3, bladder; 4, bone; 5, prostate; 6, testicular; and CNS, central nervous system.
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cavity cancer, lymphoid and hematopoietic cancer, malignant skin melanoma, other skin cancer,
pancreatic cancer, stomach cancer, and cancer of the thyroid gland (Table 2). Meta-analysis for 10
site-specific cancers was not possible; only 1 study included outcome data on bladder cancer, bone
and articular cartilage cancer, colorectal cancer, gallbladder cancer, kidney cancer, liver cancer,
ovarian cancer, prostate cancer, testicular cancer, and uterus cancer (eTable 5 in the Supplement).
Additional Analyses
The full details of the additional analyses are reported in eFigures 1-9 in the Supplement. We noted
that the results were potentially different when we examined the outcomes by considering cancer
types according to association with smoking or sex hormones. An increased risk of smoking-related
Table 2. Main Results ofMeta-analysis for Association of Anorexia NervosaWith Cancera
Outcome of Interest
Studies,
No.
Participants
With Anorexia
Nervosa, No.
Cancer
Cases,
No.
Pooled RR
(95% CI)
RR of Largest Study
(95% CI)
P Value
for
Effect
Estimate I2 (95% CI)
95%
Prediction
Intervalb
P Value for
Heterogeneity Confidence
All Cancer
Incidence in both
sexes
2 26 669 416 0.97 (0.88-1.07) 0.98 (0.88-1.08) .54 0 (NA) NA .40 Low (risk
unlikely)
Incidence in women 4 38 117 517 0.97 (0.89-1.06) 0.97 (0.88-1.08) .53 0 (0-85) 0.80-1.18 .57 Moderate
(risk
unlikely)
Incidence in men 2 1864 25 1.09 (0.73-1.65) 1.08 (0.71-1.66) .67 0 (NA) NA .82 Low (not
conclusive)
Site-Specific Cancer
Brain and central
nervous system
Incidence in both
sexes
2 26 669 45 2.31 (0.58-9.12) 1.34 (0.95-1.89) .23 72 (NA) NA .06 Low (not
conclusive)
Incidence in
women
3 30 814 43 1.14 (0.81-1.62) 1.20 (0.80-1.70) .45 0 (0-90) 0.12-10.89 .78 Low (not
conclusive)
Incidence in men 2 1864 9 4.52 (0.89-22.97) 2.30 (1.00-5.20) .07 68 (NA) NA .08 Low (not
conclusive)
Breast
Incidence in
women
5 38 392 108 0.60 (0.50-0.74) 0.60 (0.50-0.80) <.001 0 (0-79) 0.44-0.83 .66 High
(convincing)
Mortality in
women
2 28 663 18 1.22 (0.31-4.77) 2.10 (1.30-3.60) .78 69 (NA) NA .07 Low (not
conclusive)
Cervix, incidence in
women
2 24 805 23 0.69 (0.45-1.07) 0.70 (0.40-1.00) .10 0 (NA) NA .85 Low (not
conclusive)
Esophagus, incidence
in women
2 24 805 6 6.10 (2.30-16.18) 5.10 (1.80-14.60) <.001 0 (NA) NA .35 Low (not
conclusive)
Lip and oral cavity,
incidence in women
2 8160 2 2.00 (0.27-14.73) 3.20 (0.10-17.40) .49 0 (NA) NA .57 Low (not
conclusive)
Lung
Incidence in both
sexes
2 26 650 37 1.50 (1.06-2.12) 1.57 (1.07-2.30) .02 0 (NA) NA .58 Low
(suggestive)
Incidence in
women
3 30 814 38 1.77 (1.25-2.50) 1.60 (1.10-2.40) .001 0 (0-90) 0.19-16.46 .54 Low
(suggestive)
Lymphoid and
hematopoietic,
incidence in women
3 30 814 36 1.83 (0.78-4.30) 1.10 (0.80-1.60) .16 57 (0-88) 0-17025 .10 Low (not
conclusive)
Malignant skin
melanoma, incidence
in women
3 30 814 56 1.10 (0.84-1.44) 1.10 (0.80-1.50) .49 0 (0-90) 0.19-6.39 .38 Low (not
conclusive)
Other skin cancer,
incidence in women
2 28 663 50 1.12 (0.82-1.52) 1.10 (0.80-1.50) .48 0 (NA) NA .56 Low (not
conclusive)
Pancreas, incidence
in women
2 24 805 7 1.94 (0.87-4.34) 1.80 (0.80-4.30) .10 0 (NA) NA .54 Low (not
conclusive)
Stomach, incidence in
women
2 8160 9 1.51 (0.73-3.11) 1.40 (0.60-2.70) .27 0 (NA) NA .48 Low (not
conclusive)
Thyroid gland,
incidence in women
3 30 814 18 0.97 (0.59-1.60) 0.90 (0.50-1.70) .91 0 (0-90) 0.04-24.85 .88 Low (not
conclusive)
Abbreviations: NA, not available; RR, risk rate.
a Cancer outcomes with 2 or more studies for meta-analysis.
b Prediction intervals and I2 95% CIs were inestimable with fewer than 3 studies.
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cancer incidence was observed in womenwith anorexia nervosa (4 studies; RR, 1.59; 95% CI,
1.17-2.16; P = .003; I2, 58%) but not with non–smoking-related cancers (4 studies; RR, 0.89; 95% CI,
0.73-1.09; P = .27; I2, 40%). In addition, anorexia nervosa was associated with decreased risk of
developing cancers occurring in hormone-sensitive tissues compared with those without anorexia
nervosa or the general population (5 studies; RR, 0.69; 95% CI, 0.55-0.87; P = .002; I2, 27%).
For the secondary outcome of breast cancer incidence, findings remained largely consistent
after considering parity status (3 studies in parous women; RR, 0.48; 95% CI, 0.36-0.62; P < .001; I2,
0%; 3 studies in nulliparous women: RR, 0.74; 95% CI, 0.55-0.99; P = .05; I2, 0%) and age at
receiving first diagnosis of anorexia nervosa (3 studies in women aged <20 years: RR, 0.30; 95% CI,
0.08-1.13; P = .08; I2, 76%; 3 studies in women aged20 years; RR, 0.63; 95% CI, 0.47-0.84;
P = .002; I2, 0%), but some analyses may have led to insufficient statistical power.
No differences in conclusions were observed in post hoc sensitivity analyses after excluding
studies that had potential overlapping populations. Finally, given the number of individual study
estimates available per outcome (<10 studies) and reporting variability for specific sites of cancer
events, assessment of small study effects (publication bias) for pooled analyses was considered not
feasible.15
Discussion
To our knowledge, this is the first systematic review andmeta-analysis to assess the totality of
evidence regarding the association of anorexia nervosa with cancer risk. Although the scientific
understanding of the extent of the epidemiological evidence underlying the associations of anorexia
nervosa with cancer has developed within the past decades, only a minority of associations of
Figure 3. Association of Anorexia NervosaWith Risk of Cancer
Weight,
%
Increased Risk
of Cancer
Decreased Risk
of Cancer
0.01 1010.1
RR (95% CI)
Primary Outcome
4.55
9.68
12.96
72.82
100.00
Participants With
Anorexia Nervosa
186
208
6009
NA
NA
1678
1864
2337
24 332
26 669
Cancer
Cases
2
3
29
NA
NA
23
25
27
389
416
RR
(95% CI)
NA
NA
1.30 (0.20-4.70)
1.08 (0.71-1.66)
1.09 (0.73-1.65)
0.82 (0.55-1.23)
0.98 (0.88-1.08)
0.97 (0.88-1.07)
0.39 (0.08-1.13)
2.00 (1.30-2.90)
Heterogeneity: I2 = 0.0%, P = .57
Incidence, women
Mellemkjaer et al,12 2001
Michels and Ekborn,13 2004
Karaminis et al,25 2014
Mellemkjaer et al,28 2015
2151
7303
6009
22 654
38 117
25
52
74
366
517Random-effects meta-analysis
0.80 (0.52-1.18)
0.92 (0.69-1.21)
1.10 (0.80-1.30)
0.97 (0.88-1.08)
0.97 (0.89-1.06)
Mellemkjaer et al,12 2001
6.75
6.08
93.92
100.00
100.00
100.00
93.25
100.00
Incidence, men
Mellemkjaer et al,28 2015
Random-effects meta-analysis
Heterogeneity: I2 = 0.0%, P = .82
Incidence, both
Random-effects meta-analysis
Heterogeneity: I2 = 0.0%, P = .40
Mellemkjaer et al,28 2015
Mellemkjaer et al,12 2001
Mortality, both
Heterogeneity: NA
Mortality, women
Random-effects meta-analysis
Korndörfer et al,32 2003
Heterogeneity: NA
Random-effects meta-analysis
Karaminis et al,25 2014
The size of each box indicates the effect of each study by weight assigned using the random-effects model; diamond, estimated effect size; width of diamond, the precision of the
estimate (95% CI); NA, not applicable; and RR, risk ratio.
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anorexia nervosa with risk of developing cancer in specific cancer sites have supporting or suggestive
evidence, to our knowledge. Fewer studies exist for the association of anorexia nervosa with risk of
death from cancer, to our knowledge.
Our analysis does not support the possibility of a true inverse association of anorexia nervosa
with cancer in general. Anorexia nervosa was associated with some cancers but not others. This may
illustrate the fact that cancer is a complex, multifaceted, and heterogeneous disease with
considerable variations in the scale of incidence (andmortality) of cancer types worldwide,1,5,6
particularly among young people.34 Breast cancer is the major contributor to the cancer burden
among young adults globally.5,34 Findings from our meta-analysis suggest that anorexia nervosa was
associated with decreased breast cancer incidence compared with the general female population,
with high confidence. Conversely, we found that anorexia nervosa was potentially associated with
increased risk of developing lung and esophageal cancer, but the evidence was judged as only low
confidence.
The mechanisms of these patterns of risk have yet to be fully characterized. Most cancers are
the result of many risk factors. Anorexia nervosa is a disorder associated with alterations in hormonal
profiles.2,3,35 Reduced serum concentrations of estradiol and insulin-like growth factor 1 together
with decreased lifetime exposure to estrogens owing to delayed puberty and hastenedmenopause
might partially explain why young women with anorexia nervosa may have reduced risk of breast
cancer and other hormone-sensitive tissue cancers. The extreme caloric restriction in anorexia
nervosa10-14,36 could also affect the risk of some specific cancers but not cancer incidence in general.
We noted inverse associations of breast cancer incidence with anorexia nervosa even after
considering age at receiving first diagnosis of anorexia nervosa and parity status. Parity is widely
recognized as protective against breast cancer, but breast cancer risk may be increased shortly after
childbirth. A 2019meta-analysis37 showed that comparedwith nulliparous women, parous women
had an increased risk of breast cancer that peaked about 5 years after giving birth before decreasing
after longer than 30 years. The overall pattern was driven by estrogen receptor–positive
breast cancers.37
Anorexia nervosa is a marker of calorie restriction characterized by an abnormally low body
weight or low BMI. Various forms of reduced caloric intake, such as calorie restriction or fasting, have
demonstrated a range of potential beneficial effects to help prevent malignancies and increase the
efficacy of cancer therapies.10,11,36,38 Previous studies have shown associations of high BMI with
many cancers.7-9 However, the decreased cancer risk we observed in our study was limited to
estrogen-responsive tumors, and this may suggest that the caloric restriction seen in anorexia
nervosa does not confer substantial cancer protection. The biological mechanisms underlying the
association of BMI with the risk of breast cancer are complex, with opposing effects on
premenopausal and postmenopausal risk of breast cancer.7-9,39-41 A 2016 International Agency for
Research on Cancer report42 acknowledged consistent inverse associations of BMI with the risk of
premenopausal breast cancer but inconsistent findings from studies that evaluated the effect of
waist circumference or weight gain.
An increased risk was found for smoking-related cancers in women. However, the increased risk
of developing lung or esophageal cancer does not seem to be attributable to a higher prevalence of
smoking among women with anorexia nervosa. For example, in a 2016 meta-analysis43 evaluating
the association of smoking prevalence with eating disorders, people with bulimia nervosa were
significantly more likely to be lifetime smokers than healthy controls but not people with anorexia
nervosa. Similarly, there was no difference in the proportion of current smokers among people with
anorexia nervosa and healthy controls, while there was an increased proportion of current smokers
among people with bulimia nervosa compared with healthy controls. These findings suggest that
there may be a need for continued surveillance of symptoms suggestive of cancers of the respiratory
tract system among patients with anorexia nervosa and for identification and evaluation of
evidence-based health promotion interventions in patients with anorexia nervosa.
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A number of noncausal explanations have been offered to account for the association of
anorexia nervosa with cancer. Psychiatric comorbidity is common in anorexia nervosa2,4 and could
affect cancer development or diagnosis. The presence of dense breast tissuemay increase the risk of
developing breast cancer.44,45 However, the role that the density of breast tissuemay play in cancer
development remains underexplored in anorexia nervosa and requires further research. Patients
with anorexia nervosa might experience decreased rates of cancer screening as their condition
worsens. Symptoms of anorexia nervosa might mask symptoms of cancer, and patients might be less
willing to undergo examinations, such as mammograms. Somemay suggest that since patients with
anorexia nervosa have a higher mortality rate than the general population,23,24,46,47 those who
survive anorexia nervosa may also be less susceptible to dying of cancer compared with the general
population. However, we found no decreased all-cancer incidence rates in cohort studies, so this is an
unlikely explanation.
Limitations
There are some limitations to be noted regarding our study. Similar to other meta-analyses of
observational studies, there is methodological and clinical heterogeneity in the included studies in
design, patient populations, and outcomes. We used study-level data instead of individual patient
data, so the small number of studies and events for most site-specific cancers limited the sensitivity
analyses that could be conducted to account for heterogeneity in the absence of patient-level data.
Furthermore, our resultsmight have limited generalizability because the cohort studiesweremostly
conducted in Western and Northern countries, and there were no reports from low- to middle-
income countries with lower prevalence and incidence of anorexia nervosa. Meta-analysis of
observational studies are prone to bias and confounding factors, including family history of cancer,
smoking, alcohol, physical activity, and nutritional deficiency, that are inherent in the individual
studies. Although we adopted reproducible definitions that will enhance cross-study comparisons,
our study was challenged by the reporting of events in studies. None of the individual studies
examined and reported all of the cancer outcomes of interest. Also, incomplete reporting was
common in the literature and limited our possibilities to optimally synthesize the data for some
specific cancers. It is important that future observational studies thoroughly report themethods and
results for all outcomes of interest to ensure inclusion in future evidence syntheses. Reporting
guidelines, such as the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline,48 should be rigorously adopted and implemented for individual study reports.
Small study effects (ie, publication bias) were not quantitatively assessed, as there were inadequate
numbers of included studies to properly assess a funnel plot or usemore sophisticated regression-based
methods. Further insights may be gained from analyses of large clinical and administrative databases
with the power to examine the association of anorexia nervosa with specific cancers.
Conclusions
The association of anorexia nervosa with the risk of cancer has been studied in the biomedical
literature. In general, we had low confidence in observational associations of anorexia nervosa with
the risk of 20 outcomes, but there was supporting evidence frommeta-analysis for 2 outcomes (all
cancer combined and breast cancer). Other associations could also be valid (eg, lung cancer and
esophageal cancer), but there is still uncertainty about the associations and the role ofmodifiable risk
factors. There is still paucity of epidemiological data in many of the explored associations, and the
number of individual studies is limited for most cancer outcomes. To draw firmer conclusions, we
needmore prospective cohort studies and large collaborations with better assessment of the
complex connections among anorexia nervosa, losing body weight, and cancer.
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